MAPS Act
Rep. Matsui and Rep. Crenshaw Introduce the MAPS Act to Protect Medicine Supply Chains
The MAPS Act was recently introduced in the House and is currently being reviewed by the House Committee on Energy and Commerce. It is in the early stages of the legislative process and is considered active. There are no upcoming votes scheduled at this time.
Legislative Progress
This bill has support from both parties and addresses a popular issue, but it still needs to move through committees and find time on the busy voting schedule.
Key Points
Impact Analysis
Personal Impact
Life & Work
Small pharmaceutical manufacturers and pharmacies could benefit from greater supply chain transparency, helping them anticipate and prepare for shortages. However, some smaller manufacturers may face new information-sharing burdens as the government maps supply chains and tracks production volumes at registered establishments.
“the location of establishments registered under subsection (b), (c), or (i) of section 510 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360) involved in the production of active pharmaceutical ingredients and finished dosage forms”
Programs
Disabilities
Milestones
Referred to the House Committee on Energy and Commerce.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Related News
6 articles
AHA Calls on Congress to Shield Medical Supply Chains from Tariffs
The American Hospital Association (AHA) is urging Congress to pass the 'Mapping America’s Pharmaceutical Supply Act' to use data analytics to identify and predict supply chain vulnerabilities and address weaknesses before disruptions occur, amid concerns over tariffs on critical drugs.
Congress Wants to Map the Pharmaceutical Supply Chain
The bipartisan MAPS Act mandates the creation of a national database to map essential medicine supply chains. It proposes financial support, such as grants and tax credits, to encourage domestic production of active pharmaceutical ingredients (APIs) and reduce dependency on foreign sources.
Is the pharmaceutical sector prepared for a Heparin shortage?
Industry experts and the American Heart Association have called for the revival of the Mapping America's Pharmaceutical Supply Act to identify weak points and strengthen the system before a crisis hits, highlighting the vulnerability of the heparin supply chain to geopolitical events.
Source Information
Document Type
Congressional Bill
Official Title
MAPS Act
Data Sources
Sponsor
Cosponsors
(1)Analysis generated by AI. Always verify with official sources.